Translational Medicine Drug Development

Global Leader in Biotechnology Consulting & Drug Development

Driving Innovation, Strategic Growth & Risk Management in Life Sciences

Core Competencies

Advancing innovative therapies by leading cross-functional teams in developing cutting-edge immunological treatments. With expertise from biomarker validation to regulatory submissions, consistently achieved success in moving products from concept to clinical trials. Skilled in driving strategic initiatives that translate scientific research into globally impactful treatments while navigating complex regulatory landscapes.

A collaborative, highly innovative, and strategic executive who has shown value by:

●Secured $2M funding, advancing microbiome platform to clinical trial stage.

●Led successful FDA-approved pre-clinical studies for antibodies targeting viral diseases.

●Developed immunoassays for antibody potency, facilitating major product launches.

●Achieved 100% trial success with Dengue antibody, securing $1M in state funding.

●Presented in BioFlorida's Moonshot category, elevating company visibility with investors.

Core Competencies

Executive & Scientific Leadership Project Management Asana Risk Assessment & Mitigation

Healthcare & Biotech Market Trends Regulatory & FDA Submissions Strategic Consulting

Preclinical & Clinical Development Biologics, siRNA, mAbs Commercialization Strategies

Professional Achievements

Patents:

■US-202********-A1 Hyperimmunized Egg Product for Treating or Preventing Alcoholic Liver Disease and Graft-Versus-Host Disease

■WO2023240028 Aquatic Feed Pellets and Method of Preparation

■0073766 Methods for Purifying IgY Antibodies

■CV-0070, Glucosamine and Egg for Reducing Inflammation

■CV-0121, Dry Acid-Chitosan Complexes

■CV-0124, Highly Purified Cytokine Activating Factor and Method of Use

■Highly Purified Cytokine Inhibitory Factor and Methods of Use

Publications:

■Immunoglobulin Y antibodies against cytolysin reduce ethanol-induced liver disease in mice. Noemí Cabré, et.al. Hepatology. 2023;78:295-306.

■Santana E et.al. Journal of Investigative Dermatology. 111(6): 1172-7, Dec 1998.

■Iyer, S.V. et. al. Mol. Cell Biol. 11(10):4863-4875.

■Iyer, S.V. et.al. Gamete Research 22(1):37-50, 1989.

Complete list of published work in My NCBI:

URL: https://www.ncbi.nlm.nih.gov/myncbi/1d5nWVSewjOsLN/bibliography/public/

Professional Experience

Professional Experience

Prolindox

Senior Consultant Aug 2023 - Present

Transforming early-stage biotech into a product-driven company by aligning R&D with business strategy.

Led regulatory strategy & risk assessment for IND submission of small molecule drugs targeting oxidative stress.

Shifted company focus from academic research to commercialization, streamlining FDA submission planning.

Presented at BioFlorida's Moonshot event, enhancing investor engagement and funding opportunities.

Key Impact: Positioned the company for investor funding by aligning business strategy with R&D.

ProdIgY Biotech

Senior Executive Aug 2014 - Oct 2022

Led strategy, risk management, and funding for antibody therapeutics & microbiome-based treatments.

Secured $2M in funding, driving microbiome editing therapies toward clinical trials.

Developed trend-based risk mitigation strategies for emerging biopharmaceutical markets.

Managed regulatory frameworks, FDA submissions, and product development pipelines.

Key Impact: Led strategic consulting initiatives resulting in accelerated IND approvals.

Avianax

Director Aug 2011 - Oct 2013

Drove cross-functional collaboration, aligning research with regulatory pathways for commercialization.

■Secured $750K in SBIR Phase II funding for therapeutic antibodies targeting lethal viruses.

■Developed preclinical strategies for Dengue, Hantavirus, and Rabies antibodies in collaboration with USAMRID.

■Key Impact: Successfully transitioned research assets to clinical-stage development.

Proplex Technologies

Consultant Sep 2010 - Apr 2011

Architected early-stage biotech start-up, managing $100K budget and securing funding to advance biomarker validation for cancer diagnostics. Drove business development through partnerships and licensing opportunities.

Key Skills: Business Development, Biomarker Validation, Research Funding, Strategic Partnerships

■Developed immunoassay to measure biomarkers in patient serum, advancing cancer diagnostics.

■Secured $100K Double Helix funding and Temple University grant, driving company growth.

■Analyzed 100+ cancer serum samples, identifying elevated GASP-1 in brain and liver cancers.

■Achieved $200K investment and licensing deals with biotech companies in Far East.

Arkion Life Sciences

VP, R & D Aug 1997 – Feb 2011

Bridging R&D with commercialization in biotech and pharmaceutical industries.

Led cross-functional teams across manufacturing, regulatory, and business units.

Secured strategic funding & licensing partnerships, aligning scientific innovation with market opportunities.

Key Impact: Spearheaded the sale of DuCoa plant to Nutreco for $40M, ensuring business sustainability.

Education

Ph. D Immunology Bombay University

MSc. Biochemistry The Maharaja Sayajirao University of Baroda

Subramanian Iyer

561-***-**** ***********@*****.***

linkedin.com/in/subramanian-iyer-990a95

subramanianiyer.com Complete Portfolio

Contact this candidate